Episode 55: Type 2 Diabetes - how sweet it isn't

Episode 55 starts off a "sweet" new topic - type 2 diabetes. In the first podcast on this topic we talk about the whole issue of the diagnosis of diabetes, how to make the diagnosis and to some degree what the diagnosis means. Read more »

Episode 54: CRP - An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice- Part III

Episode 54 finishes off the whole issue of CRP measurement by looking at the evidence we have about what happens to patients when they take drugs that lower CRP - glitazones, COX-2s, fibrates, vitamin E, niacin, ezetimibe, and statins. Other than statins and maybe niacin, it doesn't look good - in contrast to Mike and James of course that is. Read more »

Episode 53: CRP - An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice- Part II

Episode 53 continues where we left with the whole CRP measurement or no measurement discussion. James and Mike start with the Reynolds Risk Score and show how even at the extremes of CRP, absolute risks only change by around +/- 2% or so. Read more »

Episode 52: CRP - An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice

Episode 52 goes back in time to look in more detail at what we talked about in episode 30; the whole issue of CRP measurement. Mike and James start at the "large" issue of intra-subject variability, then focus on the "small" impact CRP has on absolute risk assessment, and briefly discuss how "accurate" risk assessments are in the first place. Read more »

Episode 4: De-constructing Risk (or Benefit)

In our fourth installment, we apply the absolute benefit for statin therapy to our patient. Read more »

Episode 3: The Risky Business of CVD Risk Assessment

In the third session, we discuss the advantages and disadvantages of three methods to present “benefit”: changes in risk calculators, using relative risk, or the absolute benefit. We review the challenges of absolute vs relative risk (or relative vs absolute truth) and discuss patient expectations in regards to the medical miracle of prevention. Read more »

Episode 2: Evidence does not equal decision-making

In our second session we discuss the philosophy of calculating risk and the many factors that influence the application of these numbers. We each calculate risk using our personal preference for risk estimators and discuss the mystery of why these numbers are not the same. Read more »

Episode 1: Philosophy, guidelines and the truth

In this first session we offer a slightly long introduction (but not long enough to reach REM sleep). We present Mr. Guy Lines, a 45 year old male with a number of risks for cardiovascular, who we will consider over the next number of sessions on primary prevention. We lay the rocky groundwork of future podcasts; touching on patient values, the arbitrary nature of guidelines, discussing risks, the asymptomatic ‘sick’ patient, and the art (or enigma) of applying the evidence. Read more »

Syndicate content